151 related articles for article (PubMed ID: 24598892)
1. Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer.
Kim J; Nam HY; Choi JW; Yun CO; Kim SW
Gene Ther; 2014 May; 21(5):476-83. PubMed ID: 24598892
[TBL] [Abstract][Full Text] [Related]
2. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
[TBL] [Abstract][Full Text] [Related]
3. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy.
Kwon OJ; Kang E; Choi JW; Kim SW; Yun CO
J Control Release; 2013 Aug; 169(3):257-65. PubMed ID: 23562633
[TBL] [Abstract][Full Text] [Related]
5. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.
Kim J; Nam HY; Kim TI; Kim PH; Ryu J; Yun CO; Kim SW
Biomaterials; 2011 Aug; 32(22):5158-66. PubMed ID: 21531456
[TBL] [Abstract][Full Text] [Related]
6. Polymeric oncolytic adenovirus for cancer gene therapy.
Choi JW; Lee YS; Yun CO; Kim SW
J Control Release; 2015 Dec; 219():181-191. PubMed ID: 26453806
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenovirus Coated with Multidegradable Bioreducible Core-Cross-Linked Polyethylenimine for Cancer Gene Therapy.
Choi JW; Nam JP; Nam K; Lee YS; Yun CO; Kim SW
Biomacromolecules; 2015 Jul; 16(7):2132-43. PubMed ID: 26096567
[TBL] [Abstract][Full Text] [Related]
8. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model.
Jung SJ; Kasala D; Choi JW; Lee SH; Hwang JK; Kim SW; Yun CO
Biomacromolecules; 2015 Jan; 16(1):87-96. PubMed ID: 25400213
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
Kim J; Li Y; Kim SW; Lee DS; Yun CO
Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
[TBL] [Abstract][Full Text] [Related]
11. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.
Brugada-Vilà P; Cascante A; Lázaro MÁ; Castells-Sala C; Fornaguera C; Rovira-Rigau M; Albertazzi L; Borros S; Fillat C
Theranostics; 2020; 10(6):2744-2758. PubMed ID: 32194832
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.
Yoon AR; Kasala D; Li Y; Hong J; Lee W; Jung SJ; Yun CO
J Control Release; 2016 Jun; 231():2-16. PubMed ID: 26951927
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
14. Using a magnetic field to redirect an oncolytic adenovirus complexed with iron oxide augments gene therapy efficacy.
Choi JW; Park JW; Na Y; Jung SJ; Hwang JK; Choi D; Lee KG; Yun CO
Biomaterials; 2015 Oct; 65():163-74. PubMed ID: 26164117
[TBL] [Abstract][Full Text] [Related]
15. Linearized oncolytic adenoviral plasmid DNA delivered by bioreducible polymers.
Kim J; Kim PH; Nam HY; Lee JS; Yun CO; Kim SW
J Control Release; 2012 Mar; 158(3):451-60. PubMed ID: 22207073
[TBL] [Abstract][Full Text] [Related]
16. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration.
Kim PH; Kim J; Kim TI; Nam HY; Yockman JW; Kim M; Kim SW; Yun CO
Biomaterials; 2011 Dec; 32(35):9328-42. PubMed ID: 21924767
[TBL] [Abstract][Full Text] [Related]
17. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability.
Eto Y; Gao JQ; Sekiguchi F; Kurachi S; Katayama K; Maeda M; Kawasaki K; Mizuguchi H; Hayakawa T; Tsutsumi Y; Mayumi T; Nakagawa S
J Gene Med; 2005 May; 7(5):604-12. PubMed ID: 15543536
[TBL] [Abstract][Full Text] [Related]
18. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.
Choi JW; Dayananda K; Jung SJ; Lee SH; Kim D; Hu J; Bae YH; Yun CO
Acta Biomater; 2015 Dec; 28():86-98. PubMed ID: 26365317
[TBL] [Abstract][Full Text] [Related]
20. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses.
Thambi T; Hong J; Yoon AR; Yun CO
Cancer Gene Ther; 2022 Oct; 29(10):1321-1331. PubMed ID: 35444290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
